
Please try another search
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Name | Age | Since | Title |
---|---|---|---|
Peter Brooks | - | - | Scientific Advisor |
Andreas Suhrbier | - | - | Scientific Advisor |
Eicke Latz | - | - | Scientific Advisor |
Pam McCombe | - | - | Scientific Advisor |
Thian Chew | - | 2017 | Executive Chairman & CEO |
Nathan Lawrentschuk | - | 2019 | Member of Scientific Advisory Board |
Melanie Jaye Leydin | 52 | 2020 | CFO, Company Secretary & Non-Executive Director |
Louis Irving | - | 2019 | Member of Scientific Advisory Board |
Alistair William Bennallack | - | 2020 | Non-Executive Director |
Lynda Spelman | - | 2019 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review